Federico Monzon, M.D., chief medical officer of Castle Biosciences, entered the pathology field in the early 2000s and was among the first professionals to enjoy formal accredited recognition as a molecular pathologist. In that time his work has taken him from University of Pittsburgh Medical Center, Houston Methodist Hospital, and Baylor College of Medicine to a commercial role at genetic testing company Invitae before taking his current job. As an early entrant in the molecular pathology field, he has a keen perspective on where the field has been, and where it is going, experience he will call upon starting in November when he assumes the presidency of the Association for Molecular Pathology (AMP). Monzon recently took time from his schedule to chat with Clinical OMICs Editor in Chief Chris Anderson to discuss the molecular lab of today and its place in the health system of the future.
Customer Service: 866-788-9007